A novel drug molecule could potentially lead to new treatments to prevent Parkinson’s disease in younger patients, according to new research.
Novartis lines up protein degrader deal with Pfizer-allied Arvinas
Novartis wants in on the work at Arvinas, one of the early leaders in the protein degrader field that has gotten into Phase 3 with